Cefotaxime
Authors:
- 1 March 1997
- journal article
- review article
- Published by Springer Nature in Drugs
- Vol. 53 (3) , 483-510
Abstract
Cefotaxime is well established as an effective and well tolerated antibacterial drug for 3 times daily parenteral treatment of a variety of moderate to severe infections in hospitalised patients. Its frequency of administration has recently been reassessed with a 12-hourly regimen. Comparative studies in hospitalised patients with nosocomial or community-acquired lower respiratory tract infections, demonstrate the similar clinical and bacteriological efficacy of twice daily cefotaxime 1 or 2g and the same daily dose of ceftriaxone, usually administered once daily. Cefotaxime 2g twice daily was also similar in efficacy to ceftriaxone 2g once daily. Retrospective and post-marketing studies also reveal the similar efficacy of cefotaxime administered twice and 3 times daily, and pharmacoeconomic studies suggest that total direct costs of treatment with cefotaxime compared is similar to that with other third generation cephalosporins in currently used dosage regimens. When administered twice daily, cefotaxime is, thus, an effective antibacterial agent for the treatment of hospitalised patients outside the intensive care unit with a variety of mild to moderate non-CNS infections caused by susceptible organisms. When appropriately administered twice daily there is potential to lower the cost of antibacterial treatment without compromising efficacy. Recent studies involving large numbers of clinical isolates of Enterobacteriaceae from intensive care and haematology and/or oncology units in Europe and medical centres in the US confirm earlier data indicating that the antibacterial activity of cefotaxime is generally similar to that of ceftazidime and ceftriaxone, and superior to that of cefuroxime, against Enterobacteriaceae. Tested strains of both ampicillin-susceptible and -resistant Haemophilus influenzae are susceptible to low concentrations (≤0.07 mg/L) of cefotaxime, and 90% of Moraxella catarrhalis and Neiserria gonorrhoeae strains (both penicillin-susceptible and -resistant) were inhibited by cefotaxime ≤0.5 mg/L. Cefotaxime is more active than ceftazidime against methicillin-susceptible Staphylococcus aureus [minimum inhibitory concentration (MIC) ≈ 4 mg/L], S. epidermidis and Streptococcus pneumoniae, and in most studies the minimum inhibitory cefotaxime concentration for 90% (MIC90) of S. pneumoniae was ≤0.25 mg/L. The susceptibility of viridans streptococci to cefotaxime varies, but MIC90 values were generally between 0.12 and 2 mg/L. The MIC90 values of cefotaxime for Bacteroides fragilis ranged from 1.56 to 32 mg/L. The active metabolite of cefotaxime, desacetyl-cefotaxime, exhibits antibacterial activity that is generally less than that of the parent drug. There is evidence that desacetyl-cefotaxime may prolong the microbiological action of cefotaxime, particularly when both substances have inherent activity against an organism, and the synergistic interaction between cefotaxime and desacetyl-cefotaxime against some organisms is well documented. A combination of cefotaxime and desacetyl-cefotaxime exhibited synergy or partial synergy against the majority of tested susceptible Enterobacteriaceae and the majority of B. fragilis. These findings may explain in part the enhanced activity of cefotaxime in vivo compared with that expected from in vitro microbiological results. Synergy between cefotaxime and aminoglycosides has been shown for some Enterobacteriaceae. Cefotaxime and ampicillin have shown synergism against Listeria monocytogenes and cefotaxime and amoxicillin against Enterococcus faecalis. Similarly, combinations of cefotaxime with fosfomycin showed synergy against S. pneumoniae in vitro, a finding which was confirmed in vivo using the fibrin clot model. Recent studies have documented the in vitro synergistic effect between cefotaxime and vancomycin or teicoplanin against resistant strains of S. pneumoniae. A combination of cefotaxime and ofloxacin was synergistic against the great majority of Enterobacteriaceae and Pseudomonas aeruginosa and all tested S. pneumoniae. Epidemiological studies have generally indicated that the susceptibility to cefotaxime of Gram-negative aerobic bacteria, particularly Enterobacteriaceae, has remained relatively stable over a period of 3 to 5 years. Single-dose intravenous administration of cefotaxime 1 and 2g results in mean maximum plasma concentrations (Cmax) of 81 to 102 and 174 to 214 mg/L, respectively. Cmax values after intramuscular administration of cefotaxime are about one-quarter to one-third of those after intravenous administration of the same dose. The plasma concentration of cefotaxime exceeds that of desacetyl-cefotaxime for about 2 hours after single-dose intravenous administration; plasma concentrations 8 hours after a 30-minute infusion of cefotaxime 2g were 0.51 and 1.09 mg/L for cefotaxime and desacetyl-cefotaxime, respectively. Compared with healthy volunteers, plasma concentrations are somewhat higher in elderly patients with bacteraemia. After 12 hours, plasma desacetyl-cefotaxime concentrations were higher than those of cefotaxime. Earlier studies have shown, and more recent studies confirmed, that cefotaxime concentrations shown to be inhibitory to susceptible bacteria in vitro are achieved in most body tissues following administration of usual therapeutic dosages. The mean plasma elimination half-life (t½β) of 0.82 to 1.43 hours for cefotaxime and 2.02 to 2.13 hours for desacetyl-cefotaxime in healthy volunteers is prolonged in preterm and low birth-weight neonates, in elderly patients [mean creatinine clearance of 42 ml/min (2.52 L/h)], in patients with renal impairment (creatinine clearance MIC), Cmax to MIC ratio and area under the inhibitory concentration-time curve (AUIC24). After treatment with cefotaxime there was a correlation between the time > MIC and the numbers of bacteria remaining in the lungs...Keywords
This publication has 183 references indexed in Scilit:
- Cefotaxime Dosage in Infants and ChildrenClinical Pharmacokinetics, 1992
- Comparison of cefotaxime with ceftriaxone given intramuscularly 12-hourly for community-acquired pneumoniaDiagnostic Microbiology and Infectious Disease, 1992
- Evaluating the cost-effectiveness of treatment with third-generation cephalosporinsDiagnostic Microbiology and Infectious Disease, 1992
- Ascitic fluid and serum cefotaxime and desacetyl cefotaxime levels in patients treated for bacterial peritonitisDigestive Diseases and Sciences, 1991
- Antimicrobial activity of cefpirome an update compared to five third-generation cephalosporins against nearly 6000 recent clinical isolates from five medical centersDiagnostic Microbiology and Infectious Disease, 1991
- Antimicrobial activity of E-1040, a novel thiadiazolyl cephalosporin compared with other parenteral cephemsDiagnostic Microbiology and Infectious Disease, 1991
- Pharmacokinetics of cefotaxime and desacetylcefotaxime in the newbornDiagnostic Microbiology and Infectious Disease, 1989
- Evaluation of cefotaxime alone and in combination with desacetylacefotaxime against strains of Staphylococcus aureus that produce variants of staphylococcal β-lactamaseDiagnostic Microbiology and Infectious Disease, 1989
- Optimal cefotaxime dosing for gram-negative bacteremia: Effective trough serum bactericidal titers and drug concentrations 8 and 12 hr after 1- or 2-gm infusionsDiagnostic Microbiology and Infectious Disease, 1988
- Treatment of severe neonatal infections with cefotaxime. Efficacy and pharmacokineticsThe Journal of Pediatrics, 1982